Quality of life and medical care for long-term sarcoma survivors in Germany (PROSa+)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PROSa+ is a multicenter observational study combining a one-time cross-sectional questionnaire of 1,600 long-term sarcoma survivors (paper or online), up to 60 qualitative interviews, and longitudinal analyses linking existing sarcoma registries and the earlier PROSa cohort (2017–2020). The study focuses on subgroups with potential long-term risks, including bone sarcoma survivors, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, GIST (with or without long-term TKI therapy), and young adults. Data collected include patient-reported outcomes, patient-reported experiences, and socioeconomic measures, with recruitment via clinical networks, registries, and patient organizations. Participants must be adults (≥18 years) and at least five years post initial sarcoma diagnosis, with or without active disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST
* At least 5 years since initial sarcoma diagnosis
* With or without active disease
* Age ≥18 years at the time of study participation

Exclusion Criteria:

* Diagnosis of Desmoid tumors
* Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)

Where it's running

• Technical University Dresden
  Dresden, Saxony, Germany Recruiting
• NCT Heidelberg
  Heidelberg, Germany Recruiting
• Sarcoma Center Mannheim
  Mannheim, Germany Recruiting
• Deutsche Sarkom-Stiftung
  Wölfersheim, Germany Recruiting
• University Hospital Essen
  Essen, Germany Not yet recruiting

Study contacts

• Principal investigator: Martin Eichler, Dr. — TU Dresden & NCT/ UCC Dresden
• Study coordinator: Tanja Strukelj, M. A.
• Email: tanja.strukelj@ukdd.de,
• Phone: +493514587056

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive training with real-time brain feedback for childhood medulloblastoma survivors

  This study tests whether real-time brain feedback using rt-fMRI or rt-fNIRS can help children and young adults who survived childhood medulloblastoma improve attention and working memory.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07830134

• Active surveillance after immunotherapy for MMR-deficient colorectal and GI cancers

  This study looks at whether some patients with non-metastatic, MMR-deficient or MSI-H colorectal cancers can skip surgery after a strong response to immunotherapy.

  Recruiting at 3 sites University Hospital, Basel, Switzerland · Basel and 2 other locations · NCT07829081

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.